Catherine M. Tangen
#135,026
Most Influential Person Now
Catherine M. Tangen's AcademicInfluence.com Rankings
Catherine M. Tangensocial-work Degrees
Social Work
#53
World Rank
#63
Historical Rank
Gerontology
#24
World Rank
#26
Historical Rank
Download Badge
Social Work Nursing
Catherine M. Tangen's Degrees
- PhD Gerontology University of California, San Francisco
- Masters Nursing University of Washington
- Bachelors Nursing University of Washington
Why Is Catherine M. Tangen Influential?
(Suggest an Edit or Addition)Catherine M. Tangen's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Frailty in older adults: evidence for a phenotype. (2001) (16744)
- Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. (2004) (3631)
- The influence of finasteride on the development of prostate cancer. (2003) (2636)
- Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. (2004) (2473)
- Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. (2003) (2206)
- Guideline for the management of clinically localized prostate cancer: 2007 update. (2007) (1186)
- Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). (2011) (999)
- Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. (2009) (940)
- Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. (2006) (933)
- Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final Report (1995) (892)
- Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. (2006) (887)
- A Southwest Oncology Group study (1993) (869)
- Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. (2005) (805)
- Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. (2007) (721)
- Erectile dysfunction and subsequent cardiovascular disease. (2005) (635)
- Depressive Symptoms and Risks of Coronary Heart Disease and Mortality in Elderly Americans (2000) (529)
- Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. (1998) (520)
- Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci (2018) (509)
- Increased blood glucose and insulin, body size, and incident colorectal cancer. (1999) (487)
- Intermittent versus continuous androgen deprivation in prostate cancer. (2013) (471)
- An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. (1993) (434)
- Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). (2006) (429)
- Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. (1995) (364)
- Inflammation and coagulation factors in persons > 65 years of age with symptoms of depression but without evidence of myocardial ischemia. (2002) (360)
- Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. (1995) (353)
- Estrogen use, APOE, and cognitive decline (2000) (321)
- Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. (2006) (296)
- Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. (2006) (290)
- Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. (2014) (289)
- Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. (2016) (281)
- Discovery of common and rare genetic risk variants for colorectal cancer (2018) (279)
- Surgery for Recurrent Colon Cancer: Strategies for Identifying Resectable Recurrence and Success Rates after Resection (1998) (267)
- Long-term survival of participants in the prostate cancer prevention trial. (2013) (255)
- Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. (2007) (253)
- Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. (2014) (250)
- Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. (2014) (231)
- Erectile function outcome reporting after clinically localized prostate cancer treatment. (2007) (227)
- Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. (2007) (216)
- Chronic Inflammation in Benign Prostate Tissue Is Associated with High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial (2014) (212)
- Finasteride Does Not Increase the Risk of High-Grade Prostate Cancer: A Bias-Adjusted Modeling Approach (2008) (207)
- Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. (2009) (183)
- Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and non-parametric strategies for addressing them. (1998) (177)
- Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. (2003) (167)
- Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. (2005) (166)
- Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Collaborative Research Group. (2000) (164)
- Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction (2021) (163)
- Association of African-American ethnic background with survival in men with metastatic prostate cancer. (2001) (160)
- Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. (2007) (151)
- Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non–Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial (2018) (151)
- Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. (2013) (148)
- Antiandrogen withdrawal in castrate‐refractory prostate cancer (2008) (140)
- An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. (2011) (136)
- SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin. (2013) (130)
- A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. (2016) (127)
- Associations of demographic and lifestyle characteristics with prostate‐specific antigen (PSA) concentration and rate of PSA increase (2006) (125)
- Predicting prostate cancer risk through incorporation of prostate cancer gene 3. (2008) (124)
- Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-grade Prostatic Intraepithelial Neoplasia: SWOG S9917 (2011) (116)
- Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium (2010) (113)
- Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. (2011) (108)
- Do mixed histological features affect survival benefit from neoadjuvant platinum‐based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group‐Directed Intergroup Study (S8710) (2010) (105)
- Impact of previous local treatment for prostate cancer on subsequent metastatic disease. (2002) (104)
- Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. (2010) (102)
- Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. (2007) (102)
- Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. (2004) (97)
- Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). (2012) (96)
- Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A southwest oncology group study (1995) (92)
- Plasma Vitamin D and Prostate Cancer Risk: Results from the Selenium and Vitamin E Cancer Prevention Trial (2014) (91)
- Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid (1994) (88)
- Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. (2007) (86)
- Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. (2009) (84)
- Ten-year survival in patients with metastatic prostate cancer. (2003) (84)
- Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants (2018) (83)
- A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial (2021) (81)
- Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer. (2016) (79)
- Cumulative Burden of Colorectal Cancer-Associated Genetic Variants is More Strongly Associated With Early-onset vs Late-onset Cancer. (2019) (78)
- Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis (2020) (76)
- Genome-wide Modeling of Polygenic Risk Score in Colorectal Cancer Risk. (2020) (74)
- A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). (2009) (74)
- Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109. (2002) (73)
- Alcohol consumption, finasteride, and prostate cancer risk (2009) (72)
- The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794. (2008) (71)
- SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone(M)/prednisone(p) in men with androgen-independent prostate cancer (AIPCA). (2004) (71)
- Adjuvant Radiotherapy for Pathologically Advanced Prostate Cancer (2007) (71)
- Meta‐analysis of 16 studies of the association of alcohol with colorectal cancer (2020) (71)
- Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. (2019) (69)
- Prostate cancer--uncertainty and a way forward. (2012) (69)
- Shared heritability and functional enrichment across six solid cancers (2018) (67)
- Serum 25-Hydroxyvitamin D Concentrations and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial (2014) (67)
- Circulating Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3 Associate With Risk of Colorectal Cancer Based on Serologic and Mendelian Randomization Analyses (2019) (66)
- Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies (2018) (64)
- Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. (2011) (63)
- Adding genetic risk score to family history identifies twice as many high‐risk men for prostate cancer: Results from the prostate cancer prevention trial (2016) (61)
- Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710 (2014) (61)
- A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts (2017) (61)
- Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial. (2012) (56)
- Circulating Fatty Acids and Prostate Cancer Risk: Individual Participant Meta-Analysis of Prospective Studies (2014) (54)
- Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. (2008) (54)
- Insulin‐like growth factor‐I, insulin‐like growth factor binding protein‐3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial (2008) (54)
- Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916. (1999) (52)
- Nonparametric Analysis of Covariance and its Role in Noninferiority Clinical Trials (1999) (52)
- The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy. (2002) (50)
- Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study (2020) (49)
- Phase III Randomized Study of Adjuvant Radiation Therapy versus Observation in Patients with Pathologic T3 Prostate Cancer (SWOG 8794) (2005) (49)
- Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949. (2009) (48)
- Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case–control study (2011) (48)
- Selenium- or Vitamin E–Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT (2016) (47)
- Vitamin E and the risk of prostate cancer: Updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT). (2012) (46)
- Selenium Accumulation in Prostate Tissue During a Randomized, Controlled Short-term Trial of l-Selenomethionine: a Southwest Oncology Group Study (2006) (46)
- Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial. (2010) (46)
- Statin drug use is not associated with prostate cancer risk in men who are regularly screened. (2014) (45)
- Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. (2014) (44)
- SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. (2015) (43)
- Design and Progress of a Trial of Selenium to Prevent Prostate Cancer among Men with High-Grade Prostatic Intraepithelial Neoplasia (2006) (43)
- Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. (2012) (42)
- Chemoprevention of prostate cancer. (1994) (42)
- Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109. (2012) (42)
- Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study. (1992) (42)
- Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of southwest oncology group study 8894. (2004) (41)
- Nonparametric analysis of covariance for hypothesis testing with logrank and Wilcoxon scores and survival-rate estimation in a randomized clinical trial. (1999) (41)
- Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase III metastatic castration resistant prostate cancer trial (2015) (41)
- Selenium and Prostate Cancer: Analysis of Individual Participant Data From Fifteen Prospective Studies (2016) (40)
- Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details. (2016) (40)
- Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816). (2020) (40)
- The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator. (2013) (40)
- The prostate cancer prevention trial: design, biases and interpretation of study results. (2006) (39)
- Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited. (2005) (39)
- The prognostic value of hemoglobin change after initiating androgen‐deprivation therapy for newly diagnosed metastatic prostate cancer (2006) (39)
- Long-Term Effects of Finasteride on Prostate Cancer Mortality. (2019) (38)
- UPDATE OF SWOG 8794: ADJUVANT RADIOTHERAPY FOR PT3 PROSTATE CANCER IMPROVES METASTASIS FREE SURVIVAL (2008) (38)
- Is there a standard of care for pathologic stage T3 prostate cancer? (2009) (38)
- Southwest oncology group phase II study of arsenic trioxide in patients with refractory germ cell malignancies (2006) (37)
- Germline variation at 8q24 and prostate cancer risk in men of European ancestry (2018) (37)
- Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial. (2016) (36)
- Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials. (2016) (36)
- Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study. (1994) (35)
- Polygenic hazard score is associated with prostate cancer in multi-ethnic populations (2019) (35)
- Intraprostatic inflammation is positively associated with serum PSA in men with PSA <4 ng ml−1, normal DRE and negative for prostate cancer (2015) (34)
- The Prostate Cancer Prevention Trial: design, status, and promise (2003) (33)
- Summary and Recommendations from the National Cancer Institute’s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer (2016) (33)
- SWOG S0421: Phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC). (2012) (32)
- Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107 (2017) (31)
- A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695) (2021) (31)
- Insulin-Like Growth Factors and Insulin-Like Growth Factor–Binding Proteins and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial (2013) (31)
- Implementation of the Prostate Cancer Prevention Trial (PCPT). (2004) (30)
- Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer. (2007) (29)
- Serum adiponectin, C‐peptide and leptin and risk of symptomatic benign prostatic hyperplasia: Results from the prostate cancer prevention trial (2009) (29)
- Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. (2018) (29)
- Background and Update for S1602 "A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-naïve High-grade Non-muscle-invasive Bladder Cancer. (2018) (28)
- Non‐parametric analysis of covariance for confirmatory randomized clinical trials to evaluate dose–response relationships (2001) (28)
- Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. (2012) (28)
- Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916. (2007) (28)
- Finasteride Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial (2015) (28)
- Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial (2015) (27)
- Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone‐sensitive prostate cancer (2018) (27)
- Does the level of prostate cancer risk affect cancer prevention with finasteride? (2008) (27)
- Repeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention Trial. (2011) (26)
- Complementary nonparametric analysis of covariance for logistic regression in a randomized clinical trial setting. (1999) (26)
- Adjuvant continuous infusion 5-FU, whole-abdominal radiation, and tumor bed boost in high-risk stage III colon carcinoma: a Southwest Oncology Group Pilot study. (1995) (25)
- Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial (2016) (25)
- SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer. (2019) (25)
- An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk (2020) (25)
- Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees (2006) (24)
- Identifying novel susceptibility genes for colorectal cancer risk from a transcriptome-wide association study of 125,478 subjects. (2020) (24)
- A Functional Variant in NKX3.1 Associated with Prostate Cancer Risk in the Selenium and Vitamin E Cancer Prevention Trial (SELECT) (2014) (23)
- Transition of a Clinical Trial into Translational Research: The Prostate Cancer Prevention Trial Experience (2010) (23)
- African‐specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer (2020) (23)
- Recommended definitions of aggressive prostate cancer for etiologic epidemiologic research. (2020) (22)
- Phase III prostate cancer prevention trials: are the costs justified? (2005) (21)
- Vitamin E and the risk of prostate cancer: Updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT). (2012) (21)
- Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial (2018) (21)
- Genetic architectures of proximal and distal colorectal cancer are partly distinct (2020) (21)
- Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial (2016) (21)
- Phase II study of 5‐fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer. A southwest oncology group study (1995) (21)
- Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): Data from Southwest Oncology Group Study S9916. (2004) (20)
- Circulating adipokine concentrations and risk of five obesity‐related cancers: A Mendelian randomization study (2020) (19)
- A Collaborative Analysis of Individual Participant Data from 19 Prospective Studies Assesses Circulating Vitamin D and Prostate Cancer Risk. (2018) (19)
- Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial (2017) (19)
- Non-parametric covariance methods for incidence density analyses of time-to-event data from a randomized clinical trial and their complementary roles to proportional hazards regression. (2000) (18)
- Genomic analysis of male puberty timing highlights shared genetic basis with hair colour and lifespan (2020) (18)
- Moving a randomized clinical trial into an observational cohort (2013) (18)
- RESPONSE: Re: Association of African-American Ethnic Background With Survival in Men With Metastatic Prostate Cancer (2001) (17)
- Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology Re: Do Mixed Histological Features Affect Survival Benefit from Neoadjuvant Platinum-Based Combination Chemotherapy in Patients with Locally Advanced Bladder Cancer? A Secondary Analysis of Southwest Oncology Group-Directed Intergr (2011) (16)
- Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial (2018) (16)
- Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study (2018) (16)
- Surgery for Recurrent Colon Cancer (1999) (15)
- Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group Study. (2006) (15)
- A randomized controlled trial of vitamin E and selenium on rate of decline in lung function (2015) (15)
- Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-grade Prostatic Intraepithelial Neoplasia : SWOG S 9917 (2011) (15)
- Prostate cancer screening comes of age (2014) (14)
- The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy. (2008) (14)
- SWOG 1107: Parallel (randomized) phase II evaluation of tivantinib (ARQ-197) and tivantinib in combination with erlotinib in patients (Pts) with papillary renal cell carcinoma (pRCC). (2015) (14)
- Robustifying Trial-Derived Optimal Treatment Rules for A Target Population. (2019) (14)
- Associations of Serum Sex Steroid Hormone and 5α-Androstane-3α,17β-Diol Glucuronide Concentrations with Prostate Cancer Risk Among Men Treated with Finasteride (2012) (14)
- The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate‐specific antigen and biopsy outcome (2013) (14)
- Serum Oxidized Protein and Prostate Cancer Risk within the Prostate Cancer Prevention Trial (2010) (13)
- Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032. (2011) (13)
- Circulating tumor cell (CTC) counts and CTC telomerase activity (TA) as prognotic markers of overall survival (OS) in SWOG S0421: Docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer (mCRPC). (2012) (13)
- 1665: Adjuvant Radiotherapy for Pathologic T3 Prostate Cancer: Results of a Randomized, Prospective Clinical Trial with Metastasis-Free Survival Endpoint (2005) (13)
- Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial (2017) (13)
- Circadian genes and risk of prostate cancer in the prostate cancer prevention trial (2018) (12)
- Prostate-specific antigen: a misused and maligned prostate cancer biomarker. (2008) (12)
- Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease. (2015) (12)
- The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor (2020) (11)
- SWOG‐9510: evaluation of topotecan in hormone refractory prostate cancer: A southwest oncology group study (2002) (11)
- Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer (2021) (11)
- Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216) (2021) (11)
- Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci (2019) (11)
- Retention of Black and White Participants in the Selenium and Vitamin E Cancer Prevention Trial (SWOG-Coordinated Intergroup Study S0000) (2014) (11)
- Effect Of Vitamin E And Selenium On Rate Of Decline In FEV1: The Respiratory Ancillary Study To The Selenium And Vitamin E Cancer Prevention Trial (SELECT) (2011) (10)
- Treatment options for muscle‐invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin (2008) (10)
- Use of prostate-specific antigen progression (PSA-P) to predict overall survival (OS) in patients (pts) with metastatic prostate cancer (PC): Data from S9346 and S9916 (2008) (10)
- INTACT (S/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: Safety update on first 73 patients. (2021) (10)
- Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. (2019) (10)
- Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. (2004) (10)
- 470: Comparison of the Operating Characteristics of PSA for Prostate Cancer Detection for Finasteride and Placebo in the Prostate Cancer Prevention Trial (2006) (10)
- Clinical Outcomes in Men of Diverse Ethnic Backgrounds with Metastatic Castration Resistant Prostate Cancer. (2020) (10)
- Adjuvant androgen deprivation (ADT) versus mitoxantrone plus prednisone (MP) plus ADT in high-risk prostate cancer (PCa) patients following radical prostatectomy: A phase III intergroup trial (SWOG S9921) NCT00004124. (2017) (9)
- Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421) (2018) (9)
- A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: a Southwest Oncology Group Study. (2005) (9)
- 1664: Pathological Assessment of High Grade Tumors in the Prostate Cancer Prevention Trial (PCPT) (2005) (9)
- Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249) (2019) (9)
- Preliminary quality-of-life outcomes for SWOG-9346: Intermittent androgen deprivation in patients with hormone-sensitive metastatic prostate cancer (HSM1PC)—Phase III. (2012) (9)
- A sequential treatment approach to muscle-invasive urothelial cancer: A phase II Southwest Oncology Group Trial (S0219) of neoadjuvant paclitaxel, carboplatin, and gemcitabine (PCG) (2008) (9)
- Estimating Covariate-Adjusted Log Hazard Ratios for Multiple Time Intervals in Clinical Trials Using Nonparametric Randomization Based ANCOVA (2011) (9)
- Commentary: the ubiquity of prostate cancer: echoes of the past, implications for the present: "what has been will be again, what has been done will be done again; there is nothing new under the sun." ECCLESIASTES 1:9. (2007) (8)
- A randomized, phase II efficacy assessment of multiple MET kinase inhibitors in metastatic papillary renal carcinoma (PRCC): SWOG S1500. (2017) (8)
- MP65-02 A PHASE III SURGICAL TRIAL TO EVALUATE THE BENEFIT OF A STANDARD VERSUS AN EXTENDED PELVIC LYMPHADENECTOMY PERFORMED AT TIME OF RADICAL CYSTECTOMY FOR MUSCLE INVASIVE UROTHELIAL CANCER: SWOG S1011 (NCT #01224665) (2015) (8)
- Predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores, and American Urological Association symptom score. (2013) (8)
- Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries (2022) (8)
- Discussion: Strategies and Issues for the Analysis of Ordered Categorical Data From Multifactor Studies in Industry (1990) (8)
- INTACT: Phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer—SWOG/NRG1806. (2020) (7)
- Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results From the Prostate Cancer Prevention Trial. (2014) (7)
- Overall survival between African-American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC). (2018) (7)
- Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24 (2021) (7)
- 1666 SWOG S0353 PHASE II TRIAL OF INTRAVESICAL GEMCITABINE IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER WHO RECURRED FOLLOWING AT LEAST TWO PRIOR COURSES OF BCG (2012) (7)
- Phase II Evaluation of Low‐Dose Continuous 5‐Fluorouracil and Weekly Cisplatin in Advanced Adenocarcinoma of the Stomach: A Southwest Oncology Group Study (1995) (7)
- Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trial (2016) (6)
- Discovery of common and rare genetic risk variants for colorectal cancer (2018) (6)
- Absolute PSA value after androgen deprivation (AD) is a strong independent predictor of survival in new metastatic (D2) prostate cancer (PCa): Data from Southwest Oncology Group Trial 9346 (INT-0162). (2006) (6)
- Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score (2021) (6)
- Aneusomy for detection of bladder cancer recurrence: a Southwest Oncology Group study. (2007) (6)
- Finasteride, prostate cancer, and weight gain: Evidence for genetic or environmental factors that affect cancer outcomes during finasteride treatment (2008) (6)
- Effects of beam collimation on image quality. (1997) (6)
- Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention Trial (2020) (6)
- THE PROSTATE CANCER PREVENTION TRIAL AND THE FUTURE OF CHEMOPREVENTION (2008) (6)
- Evaluation of Ki 67 , p 53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy : A Southwest Oncology Group study (2006) (5)
- Surrogates for Survival or Other End Points in Oncology. (2016) (5)
- Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia? (2013) (5)
- Factors Associated with Adherence to an End-of-Study Biopsy: Lessons from the Prostate Cancer Prevention Trial (SWOG-Coordinated Intergroup Study S9217) (2014) (5)
- Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216) (2022) (5)
- Prostate-specific antigen, risk factors, and prostate cancer: confounders nestled in an enigma. (2010) (5)
- Circulating tumor cells (CTCs) in SWOG S1216: A phase 3 multicenter trial in metastatic hormone sensitive prostate cancer (mHSPC). (2016) (5)
- Lack of Low-risk Pathologic Findings in SWOG 8794 (2009) (5)
- Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study. (2021) (4)
- Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (2019) (4)
- Baseline circulating tumor cell (CTC) count as a prognostic marker of PSA response and progression in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide. (2020) (4)
- A phase II trial of piroxantrone in adenocarcinoma of the pancreas. A Southwest Oncology Group study. (1993) (4)
- SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691). (4)
- PD66-01 IMMEDIATE POST TURB INTRAVESICAL GEMCITABINE: A COST COMPARISON BASED ON SWOG S0337 (2018) (4)
- Survival outcomes and risk group validation from SWOG S0925, a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer (2020) (4)
- (2016). A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate risk. (2016) (4)
- Phase II trial of trimetrexate in untreated advanced gastric carcinoma. A Southwest Oncology Group study. (1994) (4)
- Biased hormonal therapy duration analysis makes results uninterpretable. (2009) (4)
- Association of molecular subtypes with pathologic response in a phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy (NAC) for localized, muscle-invasive bladder cancer (SWOG S1314; NCT02177695). (2020) (4)
- Survival in the prostate cancer prevention trial. (2013) (4)
- Publisher Correction: Shared heritability and functional enrichment across six solid cancers (2019) (4)
- Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421. (2018) (3)
- Prognostic value of anemia in untreated metastatic prostate cancer: a multivariate analysis of SWOG 8894 (2004) (3)
- 1333: Association of Erectile Dysfunction and Subsequent Cardiovascular Disease (2006) (3)
- Beyond GWAS of Colorectal Cancer: Evidence of Interaction with Alcohol Consumption and Putative Causal Variant for the 10q24.2 Region. (2022) (3)
- Treatment of advanced colorectal carcinoma with 5-fluorouracil, leucovorin and Roferon-A: a Southwest Oncology Study Group Study. (1994) (3)
- Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (2019) (3)
- Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration‐Resistant Prostate Cancer Treated on SWOG Study S0421 (2017) (3)
- Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial (2016) (3)
- Chronic In fl ammation in Benign Prostate Tissue Is Associated with High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial (2014) (3)
- Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction (2021) (3)
- Associations Between Polymorphisms in Genes Related to Oxidative Stress and DNA Repair, Interactions With Serum Antioxidants, and Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial (2022) (3)
- Review: Cooperative group trials — Southwest Oncology Group (SWOG) innovations in advanced prostate cancer (2009) (3)
- The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials. (2017) (3)
- Southwest Oncology Group S9921: Prolonged event-free survival in high-risk prostate cancer (PC) patients receiving adjuvant androgen deprivation. (2009) (3)
- First International Conference on Chemoprevention of Prostate Cancer (2004) (2)
- SWOG 0421: Prognostic and predictive value of bone metabolism biomarkers (BMB) in castration resistant prostate cancer (CRPC) patients (pts) with skeletal metastases treated with docetaxel (DOC) with or without atrasentan (ATR). (2012) (2)
- Clinical trials: 'Clinical integration': laudable, but challenging (2009) (2)
- Phase II trial of abiraterone acetate (AA) treatment for metastatic prostate cancer (PC) patients with a PSA of more than four following initial androgen deprivation therapy: SWOG S1014. (2015) (2)
- Variations in prostate biopsy recommendation and acceptance confound evaluation of risk factors for prostate cancer: Examining race and BMI. (2019) (2)
- Long-term consequences of intermittent and continuous androgen deprivation in older patients with metastatic prostate cancer. (2015) (2)
- Circulating tumor cell capture and analysis in a multicenter SWOG-coordinated prostate cancer trial. (2010) (2)
- Physical activity and risks of breast and colorectal cancer: A Mendelian randomization analysis (2019) (2)
- VM-26 in gastric cancer (1993) (2)
- Response to Li and Hopper. (2021) (2)
- Phase II trial of trimetrexate in untreated advanced gastric carcinoma (2004) (2)
- Does prostate volume affect accurate grading of prostate biopsies? (2006) (2)
- Phase II Trials Using Time-to-Event Endpoints (2005) (2)
- 1708 DO MIXED HISTOLOGIC FEATURES AFFECT SURVIVAL BENEFIT FROM NEO-ADJUVANT PLATINUM-BASED COMBINATION CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED BLADDER CANCER? (2010) (2)
- SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up. (2022) (2)
- Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program. (2015) (2)
- Phase II trial of piroxantrone in gastric carcinoma (1994) (2)
- Hepatoma/merbarone (2004) (2)
- Author Correction: Large-scale transcriptome-wide association study identifies new prostate cancer risk regions (2019) (2)
- SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer. (2022) (2)
- Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial (2020) (2)
- 525: Prostate Specific Antigen (PSA) as a Predictor of Adverse Pathologic Features at Prostatectomy in the Prostate Cancer Prevention Trial (PCPT) (2005) (2)
- Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men with Reduced Risk of High-grade Prostate Cancer by Finasteride (2018) (2)
- Phase II trial of amonafide in advanced pancreas cancer (1993) (2)
- Advanced Prostate Cancer and Postoperative Radiotherapy—Reply (2007) (2)
- Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction (2021) (2)
- Hemochromatosis risk genotype is not associated with colorectal cancer or age at its diagnosis (2020) (2)
- Paclitaxel gemcitabine (P-G) for patients (pts) with advanced urothelial cancer (UC) age > 70 years (yrs): SWOG 0028. (2010) (2)
- Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC). (2019) (2)
- A PHASE III BLINDED STUDY OF IMMEDIATE POST‐TURBT INSTILLATION OF GEMCITABINE VERSUS SALINE IN PATIENTS WITH NEWLY DIAGNOSED OR OCCASIONALLY RECURRING GRADE I/II NON‐MUSCLE INVASIVE BLADDER CANCER: SWOG S0337: PNFLBA‐10 (2017) (1)
- Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis (2020) (1)
- First International Conference on Chemoprevention of Prostate Cancer. Overview consensus statement. (2004) (1)
- Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia (2018) (1)
- Author Correction: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility (2019) (1)
- Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants (2018) (1)
- Erectile Dysfunction and Incidence of Cardiovascular Disease—Reply (2006) (1)
- Additional SNPs improve the performance of a polygenic hazard score for prostate cancer (2020) (1)
- Reduced Risk of Prostate Cancer With 5α-Reductase Inhibitors. (2018) (1)
- Choosing Phase II Endpoints and Designs: Evaluating the Possibilities (2012) (1)
- Circulating tumor cell counts (CTC) as prognostic of overall survival (OS) in SWOG S0421-docetaxel with or without atrasentan for metastatic castration resistant prostate cancer (mCRPC). (2012) (1)
- Do the benefits of finasteride outweigh the risks in the prostate cancer prevention trial? Commentary (2006) (1)
- Robust Risk Stratification Model Predicts Local-Regional Recurrence After Radical Cystectomy in Different Patient Cohorts (2013) (1)
- 1375P Intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC) (2022) (1)
- Prostate Cancer Screening, 2nd edition (2009) (1)
- Short- and long-term genitourinary symptom status and global quality of life (QOL) from a Southwest Oncology Group (SWOG) Trial (2005) (1)
- Prerandomization factors and utilization of neoadjuvant chemotherapy in a clinical trial of extended versus standard pelvic lymphadenectomy at the time of radical cystectomy for bladder cancer. (2014) (1)
- Everolimus (EVE) exposure as a predictor of toxicity (Tox) in renal cell cancer (RCC) patients (Pts) in the adjuvant setting: Results of a pharmacokinetic analysis for SWOG S0931 (EVEREST), a phase III study (NCT01120249). (2017) (1)
- Results of telomerase activity measurements from live circulating tumor cells captured on a slot microfilter in a phase III SWOG-coordinated prostate cancer trial (S0421). (2012) (1)
- Insulin-LikeGrowth Factor-I, Insulin-LikeGrowth FactorBinding Protein-3 andRiskof Benign Prostate Hyperplasia in the ProstateCancer PreventionTrial (2008) (1)
- Prognostic value of anemia in untreated metastatic prostate cancer: a multivariate analysis of SWOG 8894. (2004) (1)
- Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel (2020) (1)
- 1986 AN EMPIRICAL EVALUATION OF THE NATIONAL CANCER CENTER NETWORK GUIDELINES ON PROSTATE SPECIFIC ANTIGEN VELOCITY IN PROSTATE CANCER DETECTION (2010) (1)
- Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (2018) (1)
- Differential Biopsy Patterns Influence Associations Between Multivitamin Use and Prostate Cancer Risk in the Selenium and Vitamin E Cancer Prevention Trial. (2022) (1)
- Validating a local failure risk stratification for use in a prospective study of adjuvant radiation in bladder cancer. (2015) (1)
- Intake Patterns of Specific Alcoholic Beverages by Prostate Cancer Status (2022) (0)
- Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel. (2023) (0)
- Author Correction: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility (2019) (0)
- SURGERY FOR RECURRENT COLON CANCER. AUTHORS' REPLY (1999) (0)
- 910PExome sequencing of tumor samples from S1107 “Randomized phase II evaluation of tivantinib and tivantinib in combination with erlotinib in patients with papillary renal cell carcinoma (pRCC)” (2017) (0)
- Abstract 1274: Associations between genetic polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial (2017) (0)
- Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility (2017) (0)
- Large-scale integrated analysis of genetics and metabolomic data reveals potential links between lipids and colorectal cancer risk. (2022) (0)
- Re: Chemoprevention of Prostate Cancer. Author's reply (2010) (0)
- A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937. (2023) (0)
- 1197: Prognostic Value of Hemoglobin Change after Initiation of Androgen Deprivations Therapy for Newly Diagnosed Metastatic Prostate Cancer: A Multivariate Analysis of Swog 8894 (2006) (0)
- 526: The Performance Characteristics of Prostate-Specific Antigen (2005) (0)
- Bone metabolism biomarkers (BMB) and progression-free survival (PFS) in men with metastatic hormone-sensitive prostate cancer (HSPC): SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) with or without orteronel. (2020) (0)
- Author Correction: Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia (2019) (0)
- In reply [9] (2007) (0)
- Abstract B18: Interactions between finasteride and vitamin D-related polymorphisms is associated with prostate cancer risk in African American men (2015) (0)
- Predictors of survival in advanced renal cell carcinoma (RCC): Long-term results from Southwest Oncology Group trial S8949 (2008) (0)
- Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (2019) (0)
- Opportunities of Statistics for Precision Medicine in Drug Development (2017) (0)
- Innovative strategies for strengthening interpretability of covariance analysis by use of complementary parametric and nonparametric models (1997) (0)
- Author Correction: Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries (2023) (0)
- Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer (2021) (0)
- Genomic analysis of male puberty timing highlights shared genetic basis with hair colour and lifespan (2020) (0)
- Author Correction: Large-scale transcriptome-wide association study identifies new prostate cancer risk regions (2019) (0)
- Effect Of Vitamin E And Selenium On Incidence Of Physician-Diagnosed COPD: The Selenium And Vitamin E Cancer Prevention Trial (SELECT) (2010) (0)
- More on Long-Term Effects of Finasteride on Prostate Cancer Mortality. Reply. (2019) (0)
- Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer (2020) (0)
- Body size, increased blood blucose and insulin, and colorectal cancer (CRC) (1998) (0)
- 1217 THE PROSTATE CANCER PREVENTION TRIAL (PCPT) RISK CALCULATOR AND THE RELATIONSHIP BETWEEN PSA AND BIOPSY OUTCOME (2012) (0)
- Author Correction: Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia (2019) (0)
- Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial (2015) (0)
- Bone biomarkers and overall survival (OS) in men with castrate resistant prostate cancer (CRPC) and skeletal metastases: Updated results from SWOG 0421, a phase III trial of docetaxel +/- atrasentan (2016) (0)
- Vitamin E supplementation increased risk for prostate cancer in healthy men at a median of 7 years (2012) (0)
- Adjuvant androgen deprivation (AD) +/- mitoxantrone + prednisone (MP) in patients with high-risk prostate cancer (PC) post radical prostatectomy (RP): Phase III intergroup trial S9921. (2017) (0)
- Prostate-Specific Antigen and Its Role on the Prostate Cancer Prevention Trial (2009) (0)
- 1628 RISK STRATIFICATION FOR LOCAL-REGIONAL FAILURE AFTER CYSTECTOMY (2013) (0)
- Optimizing a risk stratification for local-regional failure after radical cystectomy using the SWOG 8710 cohort. (2014) (0)
- Change in plasma alpha-tocopherol associations with attenuated pulmonary function decline and with CYP4F2 missense variation. (2022) (0)
- Randomized phase II trial of gemcitabine, avelumab and carboplatin versus no neoadjuvant therapy preceding surgery for cisplatin-ineligible muscle-invasive urothelial carcinoma (MIUC): SWOG GAP trial (S2011). (2022) (0)
- Rapid Review Alert July 11 , 2013 ADVANCES In EPA & DHA Research (2013) (0)
- 5α-Reductase Inhibitor Use in Patients With Prostate Cancer. (2019) (0)
- Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial ( SWOG S 0421 ) (2018) (0)
- LAPAROSCOPIC RADICAL PROSTATECTOMY IN THE UK: DEFINING AND OVERCOMING THE OBSTACLES Francis X. Keeley Jr, (2007) (0)
- Comparison of plasma microRNAs with CTCs and PSA in patients treated on SWOG S0925, a randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone for patients with new metastatic hormone-sensitive prostate cancer. (2014) (0)
- Issue information (2013) (0)
- Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (2019) (0)
- Exploring the causal role of the human gut microbiome in colorectal cancer: Application of Mendelian randomization (2022) (0)
- PSA decline and objective response rates in White (W), Black (B), and Asian men with metastatic castration-resistant prostate cancer (mCRPC). (2019) (0)
- A phase II trial of piroxantrone in adenocarcinoma of the pancreas (1993) (0)
- Erectile dysfunction and incidence of cardiovascular disease. Authors' reply (2006) (0)
- Re: Long-term survival of participants in the Prostate Cancer Prevention Trial (2014) (0)
- Contribution Association of Symptomatic Benign Prostatic Hyperplasia and Prostate Cancer : Results from the Prostate Cancer Prevention Trial (2011) (0)
- Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated on SWOG Study S0421. (2016) (0)
- Bone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) +/- orteronel. (2018) (0)
- Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction (2021) (0)
- Survival outcomes and risk group validation from SWOG S0925, a randomized phase II study of androgen deprivation (AD) +/- cixutumumab, in new metastatic hormone-sensitive prostate cancer (mHSPC). (2020) (0)
- SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer (HSPC) (NCT01809691). (2014) (0)
- Effect Of Vitamin E And Selenium On F2-Isoprostanes, An Oxidative Stress Biomarker, And Lung Function (2012) (0)
- Large-scale transcriptome-wide association study identifies new prostate cancer risk regions (2018) (0)
- Abstract 4605: Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial (2015) (0)
- Long-term survival of subjects in the prostate cancer prevention trial. (2013) (0)
- Advanced prostate cancer and postoperative radiotherapy. Authors' reply (2007) (0)
- Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Metastatic Prostate Cancer Patients (2016) (0)
- Change in Plasma Alpha-Tocopherol Associations with Attenuated Pulmonary Function Decline and with CYP4F2 Missense Variation (2021) (0)
- Application of Mendelian randomization to explore the causal role of the human gut microbiome in colorectal cancer (2023) (0)
- Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci (2018) (0)
- Shared heritability and functional enrichment across six solid cancers (2019) (0)
- Comment on: the prostate cancer prevention trial : Design, biases and interpretation of study results. Author's reply (2006) (0)
- MP69-12 ADDED VALUE OF GENETIC RISK SCORE TO THE PROSTATE CANCER PREVENTION TRIAL (PCPT) RISK CALCULATOR: FINDINGS FROM THE PCPT STUDY (2014) (0)
- Abstract 1863: Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results from the Prostate Cancer Prevention Trial (2014) (0)
- Designs Using Time-to-Event Endpoints/Single-Arm versus Randomized Phase II Designs (2012) (0)
- Combining Asian-European Genome-Wide Association Studies of Colorectal Cancer Improves Risk Prediction Across Race and Ethnicity (2023) (0)
- Germline variation at 8q24 and prostate cancer risk in men of European ancestry (2018) (0)
- Association analyses identify 31 new risk loci for colorectal cancer susceptibility (2019) (0)
- Efficient Management of a Publicly Funded Cancer Clinical Trials Portfolio (2020) (0)
- 273: Timing of Recurrence and Outcomes Following Induction BCG for High Risk TA, T1 Bladder Cancer - A Southwest Oncology Group Trial (2004) (0)
- Genome-wide interaction study with smoking for colorectal cancer risk identifies novel genetic loci related to tumor suppression, inflammation and immune response. (2022) (0)
- TO: ALL SWOG MEMBER, CCOP AND AFFILIATE MEDICAL ONCOLOGISTS FROM: SWOG Operations Office RE: IND Safety Reports for IMC-A12 MEMORANDUM (2011) (0)
- Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci (2019) (0)
- not expected that metastases will be frequent event, simply due to very early cancer detection. (2009) (0)
- The Performance of PSA for Predicting Prostate Cancer After a Prior Negative Prostate Biopsy (2009) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Catherine M. Tangen?
Catherine M. Tangen is affiliated with the following schools:
